Updates

November 23, 2020November 23, 2020
Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their ... Read more
November 19, 2020November 17, 2020
Just Keep Swimming

Have you ever watched the movie “Finding Nemo?” If you have, you might recall the scene in which Dory, the optimistic, forgetful, and friendly ... Read more
November 19, 2020November 19, 2020
Latest NORD Webinar Offers Insights on Starting Nonprofit, Patient Registry

Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and ... Read more
November 16, 2020November 16, 2020
Clinical Trial Data Show Durable Efficacy of Cimzia, Bimekizumab

Treatment with Cimzia (certolizumab pegol) can ease eye inflammation in people with ankylosing spondylitis (AS), and reduce symptoms in those with active ... Read more
November 9, 2020November 9, 2020
Xeljanz Eases AS Symptoms in Phase 3 Trial

Treatment with Xeljanz (tofacitinib) was found to significantly ease symptoms of ankylosing spondylitis (AS) in a Phase 3 clinical trial. The results ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more

Updates

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

Just Keep Swimming

Latest NORD Webinar Offers Insights on Starting Nonprofit, Patient Registry

Clinical Trial Data Show Durable Efficacy of Cimzia, Bimekizumab

Xeljanz Eases AS Symptoms in Phase 3 Trial

Subscribe to our mailing list

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

Gilead Suspends Enrollment in Phase 3 Trials of Filgotinib in AS

UK Organization ‘Same But Different’ Announces ‘Glimmer of Hope’ Photo Contest Winner

Humira Boosts Work Productivity, Lessens Sleep Problems in AS, Study Finds

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

COVID-19 Lockdown Led to Fewer Swiss Patients Adhering to Treatment With Little Impact on Disease Activity

AS Pain Linked With Depression, Anxiety, Stress, Study Finds

Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar Photos

Ankylosing Spondylitis Is Not Your Fault

Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

Obesity Increases Risk of Worse Overall Health in AS, Study Reports

Cosentyx Effective in Active nr-axSpA, Phase 3 PREVENT Trial Shows

Same But Different Photo Contest Celebrates People With Rare Diseases

AbbVie Seeks FDA, EMA Approvals of Rinvoq for Active AS

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

TNF Inhibitors Significantly Slow Bone Damage in AS, Long-term Study Finds

EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US

IL-17 Inhibitors Can Ease Symptoms But Raise Infection Risk, Review Shows

New Streaming Channel Showcases Rare Disease Films

nr-axSpA Given Diagnostic Code on International Classification of Diseases

Year’s Use of Cimzia Can Lead to Sustained Remission, Phase 3b Trial Shows

EU Approves Under-the-skin Remsima Injectable for 5 Autoimmune Disorders

Hulio, Humira Biosimilar, Approved But Not Available Until 2023

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

Just Keep Swimming

Latest NORD Webinar Offers Insights on Starting Nonprofit, Patient Registry

Clinical Trial Data Show Durable Efficacy of Cimzia, Bimekizumab

Xeljanz Eases AS Symptoms in Phase 3 Trial

Subscribe to our mailing list

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

Gilead Suspends Enrollment in Phase 3 Trials of Filgotinib in AS

UK Organization ‘Same But Different’ Announces ‘Glimmer of Hope’ Photo Contest Winner

Humira Boosts Work Productivity, Lessens Sleep Problems in AS, Study Finds

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

COVID-19 Lockdown Led to Fewer Swiss Patients Adhering to Treatment With Little Impact on Disease Activity

AS Pain Linked With Depression, Anxiety, Stress, Study Finds

Same But Different Asks Public to Vote on ‘Glimmer of Hope’ Calendar Photos

Ankylosing Spondylitis Is Not Your Fault

Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

Obesity Increases Risk of Worse Overall Health in AS, Study Reports

Cosentyx Effective in Active nr-axSpA, Phase 3 PREVENT Trial Shows

Same But Different Photo Contest Celebrates People With Rare Diseases

AbbVie Seeks FDA, EMA Approvals of Rinvoq for Active AS

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

TNF Inhibitors Significantly Slow Bone Damage in AS, Long-term Study Finds

EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US

IL-17 Inhibitors Can Ease Symptoms But Raise Infection Risk, Review Shows

New Streaming Channel Showcases Rare Disease Films

nr-axSpA Given Diagnostic Code on International Classification of Diseases

Year’s Use of Cimzia Can Lead to Sustained Remission, Phase 3b Trial Shows

EU Approves Under-the-skin Remsima Injectable for 5 Autoimmune Disorders

Mindfulness Linked to Reduced Fatigue-associated Disability in Arthritis

Hulio, Humira Biosimilar, Approved But Not Available Until 2023

National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US